GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Enterprise Value

TG Therapeutics (TG Therapeutics) Enterprise Value : $1,942.5 Mil (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TG Therapeutics's Enterprise Value is $1,942.5 Mil. TG Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $25.7 Mil. Therefore, TG Therapeutics's EV-to-EBIT ratio for today is 75.65.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, TG Therapeutics's Enterprise Value is $1,942.5 Mil. TG Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $26.1 Mil. Therefore, TG Therapeutics's EV-to-EBITDA ratio for today is 74.42.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, TG Therapeutics's Enterprise Value is $1,942.5 Mil. TG Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $233.7 Mil. Therefore, TG Therapeutics's EV-to-Revenue ratio for today is 8.31.


TG Therapeutics Enterprise Value Historical Data

The historical data trend for TG Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Enterprise Value Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,114.53 6,749.31 2,486.05 1,653.12 2,479.61

TG Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,653.12 2,215.33 3,713.16 1,124.73 2,479.61

Competitive Comparison of TG Therapeutics's Enterprise Value

For the Biotechnology subindustry, TG Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Enterprise Value falls into.



TG Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

TG Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

TG Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TG Therapeutics  (NAS:TGTX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

TG Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1942.451/25.677
=75.65

TG Therapeutics's current Enterprise Value is $1,942.5 Mil.
TG Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.7 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

TG Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1942.451/26.1
=74.42

TG Therapeutics's current Enterprise Value is $1,942.5 Mil.
TG Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.1 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

TG Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1942.451/233.663
=8.31

TG Therapeutics's current Enterprise Value is $1,942.5 Mil.
TG Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $233.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TG Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (TG Therapeutics) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019

TG Therapeutics (TG Therapeutics) Headlines

From GuruFocus